Virtus Biotech Clinical Trials ETF
19 hedge funds and large institutions have $6.02M invested in Virtus Biotech Clinical Trials ETF in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
19% more funds holding
Funds holding: 16 → 19 (+3)
1% more capital invested
Capital invested by funds: $5.97M → $6.02M (+$51.4K)
0.3% less ownership
Funds ownership: 34.69% → 34.4% (-0.3%)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$386K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$57.5K |
| 3 |
DSC
Duncker Streett & Co
St. Louis,
Missouri
|
+$18.7K |
| 4 |
MCC
Money Concepts Capital
Palm Beach Gardens,
Florida
|
+$9.21K |
| 5 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$2.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$240K |
| 2 |
Rockefeller Capital Management
New York
|
-$187K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$67.8K |
| 4 |
Morgan Stanley
New York
|
-$11.6K |
| 5 |
LPL Financial
San Diego,
California
|
-$10.8K |
BBC Hedge Fund Activity: Q4 2022 in Review
19 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2022, worth a combined $6.02M — up 0.86% from $5.97M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BBC positions and 1 closed out — a net gain of 5 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $386K. The largest seller was Osaic Holdings, cutting an estimated $240K.
- 19 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2022, up from 16 in Q3 2022.
- Funds reported $6.02M of Virtus Biotech Clinical Trials ETF stock for Q4 2022, up 0.86% quarter-over-quarter.
- 6 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2022 and 1 closed out, a net change of +5 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2022 was Susquehanna International Group, an estimated $386K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q4 2022 was Osaic Holdings, an estimated $240K sold.
Based on aggregated 13F filings for Q4 2022.